Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab in refractory unstable angina (CAPTURE)
NCT00269906Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 1993
- Primary completion
- Dec 1995
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in unstable angina comparing Abciximab with Placebo (2 arms). Primary endpoint: Death, Myocardial Infarction, or Urgent Intervention at 30 days. Started May 1993; status: completed.
02
Drugs
abciximab
03
Conditions
unstable angina
Beyond the preview
Go deeper on NCT00269906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269906.